David MD - Inovio Pharmaceuticals Senior Development
| INO Stock | USD 4.19 0.18 4.49% |
Executive
David MD is Senior Development of Inovio Pharmaceuticals
| Address | 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 |
| Phone | 267 440 4200 |
| Web | https://www.inovio.com |
Inovio Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.3991) % which means that on every $100 spent on assets, it lost $0.3991. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.9142) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharmaceuticals' management efficiency ratios could be used to measure how well Inovio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -1.09. At this time, Inovio Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 29th of November 2024, Other Current Assets is likely to grow to about 6.9 M, while Total Assets are likely to drop about 131.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert Yang | Elevation Oncology | N/A | |
| Esq CPA | Ocean Biomedical | 59 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Erika Trahan | Novavax | N/A | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| Edward Berg | Vaxart Inc | 60 | |
| Shaily Garg | Vaxart Inc | N/A | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Sean Tucker | Vaxart Inc | 56 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| Biren Shah | Elevation Oncology | N/A | |
| Candice Masse | Elevation Oncology | N/A | |
| JD Esq | Novavax | 53 | |
| Robert MD | Novavax | N/A | |
| Elaine OHara | Novavax | 56 | |
| Silvia MBA | Novavax | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| MD MBA | Ocean Biomedical | 59 | |
| Rajesh Kapoor | Vaxart Inc | N/A | |
| Ian Watkins | Novavax | 61 | |
Management Performance
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.4 |
Inovio Pharmaceuticals Leadership Team
Elected by the shareholders, the Inovio Pharmaceuticals' board of directors comprises two types of representatives: Inovio Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inovio. The board's role is to monitor Inovio Pharmaceuticals' management team and ensure that shareholders' interests are well served. Inovio Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inovio Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Asli Gevgilili, Chief Officer | ||
| Jeffrey Skolnik, Senior Development | ||
| Robert Juba, Senior Management | ||
| E MBA, Senior Assurance | ||
| MBA MA, Senior Development | ||
| Ben Matone, Director Relations | ||
| Laurent Humeau, Chief Scientific Officer | ||
| Thomas Hong, Manager Relations | ||
| Daniel Jordan, VP Operations | ||
| Robert JD, General Officer | ||
| Jacqueline Shea, President CEO | ||
| PE MBA, Senior Development | ||
| David MD, Senior Development | ||
| Peter Kies, Chief Officer |
Inovio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inovio Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (329.46) % | ||||
| Current Valuation | 37 M | ||||
| Shares Outstanding | 26.1 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 33.51 % | ||||
| Number Of Shares Shorted | 3.75 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.49 X |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.